NCT01909479终止3 期
A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting hGH Product (MOD-4023) In Adult Subjects With Growth Hormone Deficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 202
- 试验地点
- 1
- 主要终点
- Change in Trunk Fat Mass, Expressed in Kilograms Measured With Dual-energy X-ray Absorptiometry, From Baseline to Week 26
研究概览
简要总结
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 23 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women between the age of 23 to 70 years old at screening, inclusive
- •GHD subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II (2007).
- •No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with any registered or investigational r-hGH or GH secretagogue product.
- •The IGF-I level at screening ≤-1 SDS of the age and sex normal ranges according to the central laboratory measurements
- •Subjects who are on a stable diet and exercise regime and do not have plans to modify their diet or exercise for at least 12 months
- •Subject had a DXA screening and the results are interpretable according to the study plan.
排除标准
- •Women who are pregnant or breast-feeding (at least 6 months delay from childbirth or lactation)
- •Evidence of growth benign intracranial tumor within the last 12 months (determined by comparing a previous MRI to a new one obtained no more than 6 months prior to study entry to clarify dynamics of growth).
- •History of any cancer. Exceptions to this exclusion criterion include resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision. Patients with GHD attributed to treatment of intracranial malignant lesions in childhood or adulthood (or, tumors) or leukemia may also be enrolled into the study provided that a recurrence-free survival period of at least 5 years is well documented in the study record.
- •Signs of intracranial hypertension at screening
- •Heart insufficiency, NYHA class > 2 (Appendix B)
- •History of overt diabetes mellitus (including currently treated, well-controlled DM) defined according to the American Diabetes Association (ADA) Criteriaa. A history of gestational diabetes, resolved after childbirth, is not exclusionary.
- •History of Acromegaly
研究组 & 干预措施
MOD-4023
Experimental
干预措施: MOD-4023 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Change in Trunk Fat Mass, Expressed in Kilograms Measured With Dual-energy X-ray Absorptiometry, From Baseline to Week 26
时间窗: Baseline to 26 weeks
次要结局
- Change in Total Fat Mass, Expressed in Kilograms, Measured With Dual-energy X-ray Absorptiometry, From Baseline to Week 26(Baseline to 26 weeks)
- Change in Lean Body Mass, Expressed in Kilograms Measured With Dual-energy X-ray Absorptiometry, From Baseline to Week 26(Baseline to 26 weeks)
- Change in Trunk Fat Mass, Expressed in Kilograms Measured With Dual-energy X-ray Absorptiometry, From Baseline to 52 Weeks(Baseline to 52 weeks)
- Change in Trunk Fat Mass, Expressed as % Change From Baseline, Measured With Dual-energy X-ray Absorptiometry, From Baseline to 26 and 52 Weeks(26 weeks to 52 weeks)
- Trunk Fat Mass as Percentage of Total Fat Mass From Baseline to Week 26(Baseline to 26 weeks)
- Change in Biochemical Marker IGF-1(Baseline to 26 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney DiseaseMetabolic AcidosisNCT03317444Tricida, Inc.217
已完成
3 期
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)Giant Cell ArteritisNCT01791153Hoffmann-La Roche251
已完成
3 期
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1GlioblastomaNCT03776071Denovo Biopharma LLC260
Unknown
3 期
A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for FracturePostmenopausal OsteoporosisNCT05060406Luye Pharma Group Ltd.448
终止
3 期
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)Alzheimer DiseaseNCT03444870Hoffmann-La Roche1,053